Clinical trial finds finerenone reduces worsening heart failure and cardiovascular death

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial led by investigators from Brigham and Women’s Hospital, a founding member of the Mass General Brigham health care system.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup